# Safety and Efficacy Study of A0001 in Subjects With Friedreich's Ataxia

> **NCT01035671** · PHASE2 · COMPLETED · sponsor: **Penwest Pharmaceuticals Co.** · enrollment: 42 (estimated)

## Conditions studied

- Friedreich's Ataxia

## Interventions

- **DRUG:** alpha-tocopherolquinone (A0001)
- **DRUG:** alpha-tocopherolquinone (A0001)
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01035671
- **Lead sponsor:** Penwest Pharmaceuticals Co.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2011-02
- **Final completion:** 2011-03
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2011-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01035671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01035671, "Safety and Efficacy Study of A0001 in Subjects With Friedreich's Ataxia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01035671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*